HDAX Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $5M

  • Investors
  • 23

HDAX Therapeutics General Information

Description

Developer of small molecule therapeutics intended for the treatment of HDAC6-driven pathologies such as neuropathies and cardiometabolic diseases. The company is developing a targeted therapeutics platform based on a differentiated two-site binding mechanism for HDAC6, enabling the delivery of a safe, efficacious, and long-lasting treatment of diseases with high unmet medical needs.

Contact Information

Website
www.hdaxtx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 333 Bay Street
  • Suite 2400
  • Toronto, Ontario M5H 2T6
  • Canada
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 333 Bay Street
  • Suite 2400
  • Toronto, Ontario M5H 2T6
  • Canada

HDAX Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HDAX Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Early Stage VC 05-Sep-2024 $5M Completed Pre-Clinical Trials
13. Early Stage VC 14-Mar-2024 Completed Pre-Clinical Trials
12. Accelerator/Incubator 14-Mar-2024 Completed Pre-Clinical Trials
11. Grant 12-Oct-2023 Completed Pre-Clinical Trials
10. Early Stage VC 20-Jul-2023 Completed Pre-Clinical Trials
9. Accelerator/Incubator 01-Apr-2023 Completed Pre-Clinical Trials
8. Accelerator/Incubator 01-Jan-2023 Completed Pre-Clinical Trials
7. Accelerator/Incubator 14-Oct-2022 Completed Pre-Clinical Trials
6. Seed Round 29-Jul-2022 $39.6K Completed Pre-Clinical Trials
5. Early Stage VC 05-Apr-2022 $39.6K $39.6K Completed Pre-Clinical Trials
To view HDAX Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

HDAX Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small molecule therapeutics intended for the treatment of HDAC6-driven pathologies such as neuropathies and
Drug Discovery
Toronto, Canada
9 As of 2024

Cambridge, MA
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HDAX Therapeutics Competitors (3)

One of HDAX Therapeutics’s 3 competitors is Eikonizo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eikonizo Therapeutics Venture Capital-Backed Cambridge, MA
Regenacy Pharmaceuticals Venture Capital-Backed Waltham, MA
Augustine Therapeutics Venture Capital-Backed Leuven, Belgium
You’re viewing 3 of 3 competitors. Get the full list »

HDAX Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HDAX Therapeutics Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
Anges Québec Angel Group Minority
Eos BioInnovation Venture Capital Minority
HaloHealth Angel Group Minority
Ontario Centre of Innovation Not-For-Profit Venture Capital Minority
SeedFolio Venture Capital Minority
You’re viewing 5 of 23 investors. Get the full list »

Ready to get started?

Request a free trial

HDAX Therapeutics FAQs

  • When was HDAX Therapeutics founded?

    HDAX Therapeutics was founded in 2021.

  • Where is HDAX Therapeutics headquartered?

    HDAX Therapeutics is headquartered in Toronto, Canada.

  • What is the size of HDAX Therapeutics?

    HDAX Therapeutics has 9 total employees.

  • What industry is HDAX Therapeutics in?

    HDAX Therapeutics’s primary industry is Drug Discovery.

  • Is HDAX Therapeutics a private or public company?

    HDAX Therapeutics is a Private company.

  • What is HDAX Therapeutics’s current revenue?

    The current revenue for HDAX Therapeutics is .

  • How much funding has HDAX Therapeutics raised over time?

    HDAX Therapeutics has raised $5.4M.

  • Who are HDAX Therapeutics’s investors?

    Anges Québec, Eos BioInnovation, HaloHealth, Ontario Centre of Innovation, and SeedFolio are 5 of 23 investors who have invested in HDAX Therapeutics.

  • Who are HDAX Therapeutics’s competitors?

    Eikonizo Therapeutics, Regenacy Pharmaceuticals, and Augustine Therapeutics are competitors of HDAX Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »